Vaccine "renaissance" attracts huge new venture investments

The New York Times examines the surge in venture backing for biotechs involved in infectious disease research. VCs ponied up $192 million for the field in the first quarter of this year, an amount that could translate into an $800 million wager over the course of the year. Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, says the burst of new research and investment mark a renaissance of the vaccine business, though he notes that there's still no vaccine for HIV yet. It's all good for companies like Genocea, a start-up working on cheap therapies to combat viruses and bacteria.

- here's the article from The New York Times

Related article:
Gates adds $287M to HIV vaccine research Report